28 January 2021

AstraZeneca Pharmaceuticals (Phils.), Inc.

**Emergency Use Authorization (EUA) for COVID-19 Vaccine (ChAdOx1-S[recombinant]) (COVID-19 Vaccine AstraZeneca)**

This applies to the application for the issuance of Emergency Use Authorization (EUA) for COVID-19 Vaccine (ChAdOx1-S[recombinant]) (COVID-19 Vaccine AstraZeneca).

The details of the COVID-19 Vaccine AstraZeneca are as follows:

- **Product Name:** COVID-19 Vaccine (ChAdOx1-S[recombinant]) (COVID-19 Vaccine AstraZeneca)
- **Dosage Strength and Form:** 0.5 mL Solution for Injection (IM)
- **Pharmacologic category:** Vaccine
- **Storage:** Store in a refrigerator (2°C to 8°C). Do not freeze. Keep vials in outer carton to protect from light.
- **Packaging:**
  - 5 mL of solution in a 10-dose vial (clear type I glass) with stopper (elastomeric with aluminum overseal) with a plastic flip-off cap. Packs of 10 vials.
  - 4 mL of solution in an 8-dose vial (clear type I glass) with stopper (elastomeric with aluminum overseal) with a plastic flip-off cap. Packs of 10 vials.

- **Manufacturer:** Catalent Anagni S.R.L., Anagni (FR), Italy
- **Indication:** For active immunization of individuals ≥18 years old for the prevention of coronavirus disease 2019 (COVID-19).

After careful consideration of the application, with all its supporting documents and a review of local experts, the FDA has been satisfied that all the conditions for the issuance of an EUA exist as provided under Executive Order (EO) No. 121, s. 2020 entitled "Granting Authority to the Director General of the Food and Drug Administration to Issue Emergency Use Authorization for COVID-19 Drugs and Vaccines, Prescribing Conditions Therefore, and for Other Purposes," particularly:

1. Based on the totality of evidence available to date, including data from adequate and well-known controlled trials, it is reasonable to believe that the COVID-19 Vaccine AstraZeneca may be effective to prevent, diagnose, or treat COVID-19;
2. The known and potential benefits of the COVID-19 Vaccine AstraZeneca, when used to diagnose, prevent, treat COVID-19, outweigh the known and potential risks of said Vaccine as of date; and

3. There is currently no adequate, approved and available alternative to the product for diagnosing, preventing or treating COVID-19.

In issuing this EUA, reliance has been accorded to the emergency use authorization given by mature and established National Regulatory Authority (NRA) of the United Kingdom. Under Section 5 of EO No. 121, the Director General of the FDA has been granted power to implement reliance and recognition processes, and accept regulatory decisions of recognized and established regulatory authorities.

**This EUA is not a marketing authorization or a Certificate of Product Registration (CPR).** Hence, this EUA cannot be used as an authorization to market the vaccine commercially. While the evaluation process was facilitated, strict conditions on the authorization granted in this Letter shall be imposed as follows:

I. **Scope**

The scope of the EUA shall be limited as follows:

A. AstraZeneca Pharmaceuticals (Phils.), Inc. shall supply COVID-19 Vaccine AstraZeneca only to emergency response stakeholders consistent with the terms and conditions of this EUA.

"Emergency response stakeholders" shall refer to the Department of Health (DOH) or the National Task Force Against COVID-19 (NTF) or their designees authorized to procure or purchase COVID-19 Vaccine AstraZeneca in line with the COVID-19 immunization program. Designees may include hospitals (public and private), health facilities of other National Government Agencies, Local Government Units (LGUs) and other members of the Private Sector.

B. The COVID-19 Vaccine AstraZeneca shall be administered only by vaccination providers, and used only to prevent COVID-19 in individuals ages 18 and older.

"Vaccination providers" shall refer to the facility, organization, or a healthcare provider, including non-physician healthcare providers such as nurses or pharmacists, authorized by the DOH or the NTF to administer the COVID-19 Vaccine AstraZeneca in accordance with the COVID-19 immunization program.

II. **Dosage Strength, Form and Method of Administration**

The COVID-19 Vaccine AstraZeneca vaccination course consists of two separate doses of 0.5 mL each. The second dose should be administered between four (4) and twelve (12) weeks after the first dose.

COVID-19 Vaccine AstraZeneca is for intramuscular (IM) injection only, preferably in the deltoid muscle.
III. Cold Chain Management

In the absence of agreement with the DOH or NTF, AstraZeneca Pharmaceuticals (Phils.), Inc. shall provide appropriate cold chain requirements for storage, transport and handling until it is delivered to the inoculation sites, and ensure that a contingency plan is in place.

AstraZeneca Pharmaceuticals (Phils.), Inc. shall have a system of monitoring to ensure traceability and that the vaccine is consistent with the storage requirements from the manufacture and transport to the inoculation sites.

AstraZeneca Pharmaceuticals (Phils.), Inc. shall observe strict compliance with the standards for Good Distribution Practices (GDP) and Good Storage Practices (GSP) adopted pursuant to Administrative Order No. 2013-0027 including supplements thereto (i.e. WHO Technical Report Series No. 961, 2011, Annex 9 and Technical Report Series No. 992, 2015, Annex 5). AstraZeneca Pharmaceuticals (Phils.) Inc. shall allow FDA Inspectors to conduct inspection of the cold storage sites including the transport vehicles.

IV. Pharmacovigilance

AstraZeneca Pharmaceuticals (Phils.), Inc. shall have a comprehensive pharmacovigilance system for COVID-19 Vaccine AstraZeneca following system or protocol for a registered drug and biologic product as stated in the FDA Circular No. 2020-003. Submission of serious and non-serious adverse reaction reports is mandatory.

AstraZeneca Pharmaceuticals (Phils), Inc. shall ensure compliance with the COVID-19 Vaccine AstraZenecaChAdOx1-S (recombinant) (AZD1222) Risk Management Plan (RMP) along with the Philippine-specific Annex. Additional pharmacovigilance activities such as interventional and non-interventional studies (ongoing or new studies, or additional activities) shall be implemented as stated in the RMP. The RMP must be updated whenever there is a significant change which may affect the benefit-risk profile of the vaccine or when an important milestone is reached.

AstraZeneca Pharmaceuticals (Phils.), Inc. shall submit six (6) monthly summary safety reports as planned and discussed in the RMP.

V. Responsibility of Emergency Response Stakeholders and Vaccination Providers

Under FDA Circular No. 2020-036 or the Guidelines for the Issuance of Emergency Use Authorization for Drugs and Vaccines for COVID-19, the pharmacovigilance obligations and post-authorization commitments imposed in this Letter shall be shared to the fullest extent possible and applicable by the national procurer and health program implementors, and their designees. Emergency response stakeholders and vaccination providers shall have the following responsibilities.

A. Emergency response stakeholders shall:

1. Identify inoculation sites to receive the COVID-19 Vaccine AstraZeneca, and ensure appropriate storage and cold chain management is maintained in
said sites, in the absence of an agreement with AstraZeneca Pharmaceuticals (Phils.), Inc.;

2. Ensure administration of the COVID-19 Vaccine AstraZeneca is consistent with the terms of this Letter, latest product information and the COVID-19 Vaccination Program; and

3. Ensure that vaccination providers of the procured COVID-19 Vaccine AstraZeneca are aware of this Letter of Authorization and the terms herein and any subsequent amendments thereof, instructed about the means which they are to obtain and administer the COVID-19 Vaccine AstraZeneca, and provided with approved fact sheets.

B. On the other hand, vaccination providers shall:

1. Administer the COVID-19 Vaccine AstraZeneca, in accordance with this EUA, and participate and comply with the terms and training required by the DOH for the COVID-19 Immunization Program;

2. Provide fact sheets to the recipients and caregivers, and provide necessary information for receiving their second dose;

3. Obtain written informed consent from the recipient of the COVID-19 Vaccine AstraZeneca prior to vaccination;

4. Report any Adverse Events Following Immunization on the use of COVID-19 Vaccine AstraZeneca;

5. Monitor and comply with vaccine management requirements (e.g. obtaining, tracking and handling vaccine) of the DOH; and

6. Ensure that records associated with this EUA are maintained until notified by FDA. Such records shall be made available to DOH and FDA for inspection upon request.

Notwithstanding the foregoing, AstraZeneca Pharmaceuticals (Phils.), Inc. has the ultimate responsibility for monitoring the safety and quality of the COVID-19 Vaccine AstraZeneca.

VI. Validity

Unless otherwise revoked, this EUA shall be valid only within the duration of the declared public health emergency due to COVID-19, or upon issuance of a marketing authorization/CPR.

In the event that the declared public health emergency is lifted, or when a COVID-19 vaccine is registered with the FDA, this EUA shall have a provisional validity for a period of one (1) year from date of lifting of the declaration or registration of the vaccine for the sole purpose of exhausting remaining products.

This EUA is subject to revocation, suspension or cancellation due to violations of pharmacovigilance obligations and post authorization commitments, as well as any violation of the EO No. 121, and RA 3720 as amended by RA No. 9711, FDA Circular No. 2020-036, and other rules and regulations issued thereunder.

For strict compliance.